Back to Search
Start Over
Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection.
- Source :
-
Expert review of gastroenterology & hepatology [Expert Rev Gastroenterol Hepatol] 2017 Jul; Vol. 11 (7), pp. 611-622. Date of Electronic Publication: 2017 Jun 26. - Publication Year :
- 2017
-
Abstract
- Introduction: Clostridium difficile infection (CDI) is the most common nosocomial infection in the U.S. 25% of CDI patients go on to develop recurrent CDI (rCDI) following current standard of care (SOC) therapy, leading to morbidity, mortality and economic loss. The first passive immunotherapy drug targeting C.difficile toxin B (bezlotoxumab) has been approved recently by the FDA and EMA for prevention of rCDI. Areas covered: A body of key studies was selected and reviewed by the authors. The unmet needs in CDI care were ascertained with emphasis in rCDI, including the epidemiology, pathophysiology and current management. The current knowledge about the immune response to C. difficile toxins and how this knowledge led to the development and the clinical use of bezlotoxumab is described. Current and potential future competitors to the drug were examined. Expert commentary: A single 10 mg/kg intravenous infusion of bezlotoxumab has been shown to decrease rCDI by ~40% (absolute reduction ~10%) in patients being treated for primary CDI or rCDI with SOC antibiotics. Targeting C.difficile toxins by passive immunotherapy is a novel mechanism for prevention of C.difficile infection. Bezlotoxumab will be a valuable adjunctive therapy to reduce the burden of CDI.
- Subjects :
- Animals
Antibodies, Monoclonal economics
Antibodies, Monoclonal pharmacology
Antibodies, Neutralizing economics
Antibodies, Neutralizing pharmacology
Bacterial Proteins immunology
Bacterial Toxins immunology
Broadly Neutralizing Antibodies
Economic Competition
Enterocolitis, Pseudomembranous epidemiology
Humans
Recurrence
Antibodies, Monoclonal therapeutic use
Antibodies, Neutralizing therapeutic use
Clostridioides difficile
Enterocolitis, Pseudomembranous prevention & control
Secondary Prevention methods
Subjects
Details
- Language :
- English
- ISSN :
- 1747-4132
- Volume :
- 11
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Expert review of gastroenterology & hepatology
- Publication Type :
- Academic Journal
- Accession number :
- 28636484
- Full Text :
- https://doi.org/10.1080/17474124.2017.1344551